@prefix biolink: . @prefix ns1: . @prefix this: . @prefix sub: . @prefix schema: . @prefix np: . @prefix dct: . @prefix rdf: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { biolink:category biolink:Disease . sub:association rdf:object ; rdf:predicate biolink:treats; rdf:subject ; a rdf:Statement; rdfs:label "\"Zolmitriptan is contraindicated in patients with: Ischemic coronary artery disease (angina pectoris, history of myocardial infarction, or documented silent ischemia), other significant underlying cardiovascular disease, or c Warnings and Precautions ( 5.1 Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions ( 5.2 History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions ( 5.4 Peripheral vascular disease (PVD) [see Warnings and Precautions ( 5.5 Ischemic bowel disease [see Warnings and Precautions ( 5.5 Uncontrolled hypertension [see Warnings and Precautions ( 5.8 Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, or ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions ( 7.1 7.3 Concurrent administration of a monoamine oxidase (MAO)-A inhibitor or recent use of a MAO-A inhibitor (that is within 2 weeks) [see Drug Interactions ( 7.2 Clinical Pharmacology ( 12.3 Known hypersensitivity to zolmitriptan (angioedema and anaphylaxis seen) [see Adverse Reactions ( 6.2 History of coronary artery disease (CAD) or coronary vasospasm ( 4 Symptomatic Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( 4 History of stroke, transient ischemic attack, or hemiplegic or basilar migraine ( 4 Peripheral vascular disease ( 4 Ischemic bowel disease ( 4 Uncontrolled hypertension ( 4 Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan), or an ergotamine-containing medication ( 4 Monamine oxidase (MAO)-A inhibitor used in past 2 weeks ( 4 Known hypersensitivity to zolmitriptan ( 4\""; biolink:provided_by ; biolink:relation schema:MedicalContraindication . biolink:category biolink:Drug . } sub:provenance { sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"; npx:hasSignature "UFwMfnbaGsXMkKmJYORpF/4E3FM7g3KhP0yfjN0fKHKIV9GFuTXvLVRHgYEH1Yq0OYpIpgZjfYj0FkXU00esIvAETt0rGwEMQSbF10Tyn3wib73rmbaBBgmsn+KRJ3f6WReLN/Npt7VCmSII64VkrwrF7SUIXvHATMHo0rR4AlU="; npx:hasSignatureTarget this: . this: dct:created "2021-08-23T18:00:23.548+02:00"^^xsd:dateTime; dct:creator orcid:0000-0002-1468-3557; ns1:wasCreatedFromProvenanceTemplate ; ns1:wasCreatedFromPubinfoTemplate ; ns1:wasCreatedFromTemplate . }